I suspect a PR soon naming a new CEO and direction for the company. Not many pinkies out there with actual products in stores right now. GSAC can be found at WalGreens, CVS, among other big name pharmacies. Do your own DD and you will see the potential.
Posts: 204 | Registered: Apr 2006
| IP: Logged |
posted
Quick response to email questions concerning CEO and Financials:
The Company is currently being run by U.S. Marketing, Ltd. and the Board of Directors. This team has made significant progress reducing expenses and opening marketing channels (monthly expenses have dropped drastically). At this time a CEO is not necessary, but we would consider any candidate. The process of preparing GAAP financial statements for the periods of year-end 2005 and for the quarters and year-end for 2006 are in progress. We expect they will be completed and uploaded to pinksheets.com by 3/31/07. The step to become fully reporting would be determined based on expense/benefit analysis. With that said, it is recognized that moving to a larger exchange such as the AMEX is very important to attract institutional investors.
Jens Dalsgaard Managing Director Redwood Consultants, LLC 250 Bel Marin Keys Blvd. Suite A-1 Bel Marin Keys, CA. 94949
(415) 884-0348 tel (415) 884-0361 fax
If US marketing and the BOD can effectively manage the Co. without a CEO, then that saves a bunch of $$$ not having to pay a big salary. GSAC is still selling products and manking money, and the financial statements will definitely help. I really like the comment about moving to the AMEX.
Posts: 204 | Registered: Apr 2006
| IP: Logged |
posted
Read a message on another board yesterday about GSAC being in negotiations with another major pharma co. Great news if true.
With the CEO leaving, it might make sense. GSAC doesn't need him if they are going to be bought out by somebody else. It also explains the push to get the finanicals completed. A full financial audit must be completed before a transaction.
The posting also said that they had spoken with somebody at the company and they felt the pps should be at least .35 right now. After they report finanicals, they believed the pps would return to the $1.00 range.
I have a large buy order in right now on the bid to see if I can pick up some more cheap shares. With such a low float, this will blow up real fast. I have seen many low floaters like this one really take off (examples... IDWD: .09 - 1.90, GLXI: .02 - .18)
Posts: 204 | Registered: Apr 2006
| IP: Logged |
posted
I am surprised at the lack of activity here. I have followed this one for a while, and I know it should be trading much higher.
All this one needs is a little spark and it will explode. With the low float, soon to be released financials, potential uplisting, there are too many good things here for you people to not be noticing this.
I will call it right here, that this will be trading over .75 (more likely over $1.00) before the end of May.
Posts: 204 | Registered: Apr 2006
| IP: Logged |
posted
GelStat Receives Notice of Allowance for U.S. Patent for Its GelStat(TM) Migraine Product Tuesday February 6, 8:00 am ET
ST. PAUL, MN--(MARKET WIRE)--Feb 6, 2007 -- elStat Corporation (Other OTC:GSAC.PK - News), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is pleased to announce that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of its proprietary over-the-counter product, GelStat(TM) Migraine, to treat migraine headaches.
The patent application, entitled "Compositions and Methods of Treatment to Alleviate or Prevent Migrainous Headaches and Their Associated Symptoms," includes a number of key claims surrounding the Company's product formulation and its sublingual (under the tongue) delivery. GelStat Migraine is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. It is estimated that 30 million Americans suffer from migraine.
Commenting on the news, James LaFlamme, GelStat's Chairman said, "We believe the Notice of Allowance announced today represents a significant increase in the value of GelStat's intellectual property portfolio. It forms the basis for our GelStat Migraine product, as well as laying the foundation for future related work in treating other pain and inflammation related disorders. The corresponding patent should be issued within the next several months, and we are very pleased with the opportunities this new patent provides."
ABOUT GELSTAT CORPORATION
GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.
Click the following links to view supporting information on the effectiveness of GelStat Migraine:
Initial Clinical Trial of GelStat Migraine Shows it to be Effective for 83 Percent of those with Moderate to Severe Migraine
GelStat is Effective in Relieving Migraine Pain in a Double-Blind, Placebo-Controlled study
2 Minute Video Demonstrating the Product and its Successful Treatment of a Migraine Headache
The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat(TM) Arthritis is the second available product to utilize GelStat's patent pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat(TM) Sinus" and "GelStat(TM) Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."
posted
low volume does not make this feasible for profit - could never get out of it
Posts: 1220 | From: Denver, CO | Registered: Jun 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
